Johnson & Johnson (JNJ)

AI-powered earnings prediction for Johnson & Johnson (JNJ).

242.49
-1.79%
USD, 2 days ago
Market Cap
581.65B
Google

Company Overview

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Phone
732 524 0400
Headquarters
One Johnson & Johnson Plaza
New Brunswick, NJ, 08933
United States
Full-Time Employees
138,200

Key Metrics

P/E Ratio (TTM)
21.86
Forward P/E
19.24
Price to Book
7.13
Beta
0.35
Profit Margin
28.46%
Gross Margin
68.08%
Return on Equity
35.03%
Return on Assets
8.68%
Earnings Growth
48.60%
Revenue Growth
9.10%
Dividend Yield
211.00%
Dividend Rate
$5.20

Financial Health

Total Cash
$20.10B
Total Debt
$49.33B
Debt to Equity
60.50
Current Ratio
1.03
Free Cash Flow
$16.63B
Operating Cash Flow
$24.53B

Analyst Recommendations

Target Price (Mean)
$232.50
Target High
$265.00
Target Low
$155.00
Recommendation
buy
Analyst Coverage
24 Analysts

Trading Ideas

Related Stocks